Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa-Reference-Cited by-同舟云学术

Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa

Published:2019-08 Issue:8 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Mallayasamy Surulivelrajan¹,Chaturvedula Ayyappa¹,Fossler Michael J.¹²,Sale Mark¹³,Goti Vineet³,Bumpus Namandje N.⁴,Marzinke Mark A.⁴,Hendrix Craig W.⁴,Haberer Jessica E.⁵,

Affiliation:

1. UNT System College of Pharmacy, UNT Health Science Center, Fort Worth, Texas, USA

2. Trevena Inc., Chesterbrook, Pennsylvania, USA

3. Nuventra, Raleigh, North Carolina, USA

4. Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

5. Massachusetts General Hospital, Boston, Massachusetts, USA

Abstract

The Partners Demonstration Project was a prospective, open-label, implementation science-driven study of preexposure prophylaxis (PrEP) among heterosexual HIV serodiscordant couples in Kenya and Uganda. Adherence data were collected using the Medication Event Monitoring System (MEMS), and time of sexual activity was collected using the mobile phone short message service (SMS). Two plasma samples were collected at a single study visit.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00446-19

Reference37 articles.

1. US Department of Health and Human Services. 2012. FDA approves first drug for reducing the risk of sexually acquired HIV infection. https://aidsinfo.nih.gov/news/1254/fda-approves-first-drug-for-reducing-the-risk-of-sexually-acquired-hiv-infection.

2. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

3. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana

4. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

5. Global Advocacy for HIV Prevention. 2017. Ongoing and planned PrEP demonstration and implementation studies. https://www.avac.org/resource/ongoing-and-planned-prep-demonstration-and-implementation-studies. Accessed 7 May 2018.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An allopurinol adherence tool using plasma oxypurinol concentrations;British Journal of Clinical Pharmacology;2022-09-15

2. Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions;Current HIV/AIDS Reports;2020-05-19